{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:31:41Z","timestamp":1778509901330,"version":"3.51.4"},"reference-count":73,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Aspirin has been the default backbone of antiplatelet therapy after percutaneous coronary intervention (PCI) for over two decades, anchored by landmark trials that established 12-month dual antiplatelet therapy (DAPT) as the standard of care. Three developments have prompted reassessment of this paradigm: the markedly lower thrombotic risk of contemporary drug-eluting stents, the greater potency and consistency of potent P2Y12 inhibitors (ticagrelor, prasugrel), and increasing recognition that major bleeding independently worsens outcomes after PCI. Recent randomised trials have systematically tested aspirin withdrawal at varying time points. Immediate aspirin-free strategies (NEO-MINDSET, STOPDAPT-3) demonstrated an early signal of excess ischaemic events in the ACS component of enrolled populations, suggesting that aspirin remains important during the earliest post-PCI period in ACS. One-month strategies (T-PASS, ULTIMATE-DAPT, TARGET-FIRST) and three-month strategies (TWILIGHT, TICO, DUAL-ACS) showed that transition to P2Y12 monotherapy after an initial DAPT period significantly reduces bleeding without increasing ischaemic events in selected populations. Beyond one year, long-term randomised trials including the HOST-EXAM 10-year follow-up (Lancet 2026) and the STOPDAPT-2 5-year landmark analysis (Circ Cardiovasc Interv 2026), together with study-level meta-analyses (PANTHER) and recent individual patient data meta-analyses, provide converging evidence that clopidogrel monotherapy outperforms aspirin for chronic secondary prevention without excess bleeding. The choice of P2Y12 agent is critical: clopidogrel monotherapy in ACS during the first post-procedural year carries excess thrombotic risk owing to CYP2C19 pharmacogenomic variability, whereas ticagrelor and prasugrel provide more reliable protection. This review synthesises the mechanistic rationale, trial evidence across all time points, special clinical contexts (oral anticoagulation, coronary artery bypass grafting, high bleeding risk), guideline evolution, and methodological considerations, providing a practical framework for individualising post-PCI antiplatelet therapy.<\/jats:p>","DOI":"10.3390\/jcdd13050201","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:10:42Z","timestamp":1778505042000},"page":"201","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is Aspirin Still Indispensable After PCI\u2014Rethinking Dual Antiplatelet Therapy in Contemporary Practice"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0380-7298","authenticated-orcid":false,"given":"Kartik","family":"Yadav","sequence":"first","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8760-3723","authenticated-orcid":false,"given":"Sama Ehab Salah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9030-6272","authenticated-orcid":false,"given":"Mohamed","family":"Abdelgader","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4863-5801","authenticated-orcid":false,"given":"Roann","family":"Khalid","sequence":"additional","affiliation":[{"name":"General Medicine, King\u2019s College Hospital NHS Foundation Trust, London SE5 9RS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murugapathy","family":"Veerasamy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK"},{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-3036","authenticated-orcid":false,"given":"Arka","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK"},{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1985-1783","authenticated-orcid":false,"given":"Heerajnarain","family":"Bulluck","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK"},{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Neumann","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomised controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1053\/euhj.2002.3385","article-title":"Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"23","author":"Bertrand","year":"2002","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","article-title":"Long-term safety of drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenomics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1161\/ATVBAHA.107.161471","article-title":"Tissue factor in patients with acute coronary syndromes","volume":"28","author":"Brambilla","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Loeffen, R., van Oerle, R., Leers, M.P.G., Kragten, J.A., Crijns, H., Spronk, H.M.H., and Cate, H.T. (2016). Factor XIa and thrombin generation are elevated in patients with acute coronary syndrome. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158355"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e015197","DOI":"10.1161\/CIRCINTERVENTIONS.124.015197","article-title":"Aspirin-free strategy for PCI in patients with high bleeding risk: A subgroup analysis from STOPDAPT-3","volume":"18","author":"Ishikawa","year":"2025","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa2507980","article-title":"Early withdrawal of aspirin after PCI in acute coronary syndromes","volume":"393","author":"Franken","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacc.2025.10.058","article-title":"Potent P2Y12 inhibitor monotherapy vs. DAPT after PCI in patients with and without STEMI: The NEO-MINDSET substudy","volume":"87","author":"Tavares","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"T-PASS (Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome) Investigators. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: The T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after PCI in patients with acute coronary syndromes (ULTIMATE-DAPT)","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months after drug-eluting stent implantation (GLOBAL LEADERS)","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa2508808","article-title":"Early discontinuation of aspirin after PCI in low-risk acute myocardial infarction","volume":"393","author":"Tarantini","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/eurheartj\/ehae249","article-title":"Ticagrelor monotherapy for acute coronary syndrome: An individual patient data meta-analysis of TICO and T-PASS trials","volume":"45","author":"Lee","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: The TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"ref_32","unstructured":"Newby, D.E., and on behalf of the DUAL-ACS Investigators (2025, January 1). Duration of dual antiplatelet therapy after acute myocardial infarction: The DUAL-ACS randomised clinical trial. Proceedings of the ESC Congress 2025, Madrid, Spain."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Watanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Nishikawa, R., Kimura, T., Imada, K., Suwa, S., and Isawa, T. (2026). Clopidogrel versus aspirin monotherapy beyond 1 year after PCI: The final 5-year results of the STOPDAPT-2 ACS and STOPDAPT-2 total cohort. Circ. Cardiovasc. Interv., e016280.","DOI":"10.1161\/CIRCINTERVENTIONS.125.016280"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","article-title":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: A systematic review and individual patient-level meta-analysis of randomised trials","volume":"404","author":"Valgimigli","year":"2024","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.4244\/EIJ-D-25-00331","article-title":"One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: The 4D-ACS randomised trial","volume":"21","author":"Jang","year":"2025","journal-title":"EuroIntervention"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): An open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamacardio.2024.0534","article-title":"Extended clopidogrel monotherapy vs DAPT in patients with acute coronary syndromes at high ischemic and bleeding risk: The OPT-BIRISK randomized clinical trial","volume":"9","author":"Li","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS)","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.072009","article-title":"Derivation and validation of the PRECISE-HBR score to predict bleeding after percutaneous coronary intervention","volume":"151","author":"Gragnano","year":"2025","journal-title":"Circulation"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/eurheartj\/ehad362","article-title":"Personalised antiplatelet therapies for coronary artery disease: What the future holds","volume":"44","author":"Capodanno","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI)","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1161\/CIR.0b013e31823b5fee","article-title":"2011 ACCF\/AHA guideline for coronary artery bypass graft surgery: Executive summary","volume":"124","author":"Hillis","year":"2011","journal-title":"Circulation"},{"key":"ref_55","unstructured":"Yuan, X., and on behalf of the TOP-CABG Investigators (2025, January 1). De-escalated versus standard dual antiplatelet therapy after coronary artery bypass grafting: The TOP-CABG randomised trial. Proceedings of the ESC Congress 2025, Madrid, Spain."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2508026","article-title":"Ticagrelor and aspirin or aspirin alone after coronary surgery for acute coronary syndrome: The TACSI randomised trial","volume":"393","author":"Jeppsson","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2796.2005.01477.x","article-title":"Low-dose aspirin for secondary cardiovascular prevention\u2013cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation\u2013review and meta-analysis","volume":"257","author":"Burger","year":"2005","journal-title":"J. Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00380-022-02029-8","article-title":"Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease","volume":"37","author":"Graham","year":"2022","journal-title":"Heart Vessel."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"i5483","DOI":"10.1136\/bmj.i5483","article-title":"Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes","volume":"355","author":"Gargiulo","year":"2016","journal-title":"BMJ"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amjcard.2024.10.038","article-title":"Short versus one-year dual antiplatelet therapy after percutaneous coronary intervention: An updated meta-analysis","volume":"237","author":"Joseph","year":"2025","journal-title":"Am. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","article-title":"Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: The HOST-EXAM Extended study","volume":"147","author":"Kang","year":"2023","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e082561","DOI":"10.1136\/bmj-2024-082561","article-title":"P2Y12 inhibitor or aspirin after percutaneous coronary intervention: Individual patient data meta-analysis of randomised clinical trials","volume":"389","author":"Giacoppo","year":"2025","journal-title":"BMJ"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus aspirin for secondary prevention of coronary artery disease: A systematic review and individual patient data meta-analysis","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(26)00422-8","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial","volume":"407","author":"Kang","year":"2026","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jcin.2025.05.044","article-title":"Aspirin or P2Y12 inhibitor monotherapy after percutaneous coronary intervention for acute coronary syndromes","volume":"18","author":"Laudani","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/eurheartj\/ehz807","article-title":"Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes","volume":"41","author":"Storey","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/ATVBAHA.123.320448","article-title":"PAR4 antagonism in patients with coronary artery disease receiving antiplatelet therapies","volume":"44","author":"Nash","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/ehjcvp\/pvae057","article-title":"P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: A systematic review and meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa2307770","article-title":"OCT or angiography guidance for PCI in complex bifurcation lesions","volume":"389","author":"Holm","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMoa2305861","article-title":"Optical coherence tomography-guided versus angiography-guided PCI (ILUMIEN IV)","volume":"389","author":"Ali","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/5\/201\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:55:38Z","timestamp":1778507738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/5\/201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":73,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcdd13050201"],"URL":"https:\/\/doi.org\/10.3390\/jcdd13050201","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]}}}